CN105001256A - Preparation method of choline alfoscerate crystal - Google Patents
Preparation method of choline alfoscerate crystal Download PDFInfo
- Publication number
- CN105001256A CN105001256A CN201510497093.8A CN201510497093A CN105001256A CN 105001256 A CN105001256 A CN 105001256A CN 201510497093 A CN201510497093 A CN 201510497093A CN 105001256 A CN105001256 A CN 105001256A
- Authority
- CN
- China
- Prior art keywords
- mixture
- preparation
- crystal
- concentrated
- choline glycerophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008777 Glycerylphosphorylcholine Substances 0.000 title claims abstract description 57
- 239000013078 crystal Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229960004788 choline alfoscerate Drugs 0.000 title abstract 5
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 claims abstract description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 52
- 238000001035 drying Methods 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- 235000011152 sodium sulphate Nutrition 0.000 claims description 5
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 4
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 4
- 235000011151 potassium sulphates Nutrition 0.000 claims description 4
- 230000008719 thickening Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 238000001914 filtration Methods 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- -1 preferably Chemical compound 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preparation method of a choline alfoscerate crystal. The preparation method comprises steps as follows: (1), a mixture M1 is prepared by mixing choline alfoscerate and alcohol; (2), the mixture M1 and sulfate are mixed, cooled and subjected to first filtering, a filtrate is taken, and a mixture M2 is obtained; (3), the mixture M2 is subjected to first concentration, and a mixture M3 is prepared; (4), the mixture M3 and an organic solvent are mixed and subjected to second concentration, and a mixture M4 is obtained; (5), the mixture M4 is dried under reduced pressure, and the choline alfoscerate crystal is obtained. The choline alfoscerate crystal prepared with the method has lower water absorption, high purity and better health care property and medical value.
Description
Technical field
The present invention relates to the preparation field of Choline Glycerophosphate, particularly, relate to a kind of preparation method of Choline Glycerophosphate crystal.
Background technology
Choline Glycerophosphate has the water-soluble substances by obtaining after the main phospholipid PC (phosphatidylcholine) forming cytolemma sloughs 2 lipid acid.Choline Glycerophosphate extensively exists in vivo, is mainly present in emulsion and body fluid.Choline Glycerophosphate can improve the cognitive ability of brain; fabulous preventive effect is had to senile dementia; can also promote that teenager's health is grown up; improve teen-age memory capability; the fatty acid permeation that Choline Glycerophosphate can also protect hepatic tissue to produce from poisonous tetracol phenixin and high lipoprotein food effectively; there is the effect of lipidemia, protection blood vessel; there is high health properties and pharmaceutical use, be therefore widely used in medicine, healthcare products and functional foodstuff.
At present, in prior art, commercially available Choline Glycerophosphate mainly obtains with the extraction of ethanol single from the byproduct of soybean, the Choline Glycerophosphate that this method obtains places the moisture easily absorbed in air in atmosphere, water-intake rate is too high, thus cause the purity degradation of Choline Glycerophosphate, thus weaken health properties and the pharmaceutical use of Choline Glycerophosphate greatly.
Summary of the invention
The object of this invention is to provide a kind of preparation method of Choline Glycerophosphate crystal, the water-intake rate of the Choline Glycerophosphate crystal prepared by the method is lower, purity is high, have good health properties and pharmaceutical use.
To achieve these goals, the invention provides a kind of preparation method of Choline Glycerophosphate crystal, this preparation method comprises:
(1) by Choline Glycerophosphate and the obtained mixture M 1 of alcohol mixing;
(2) by described mixture M 1 and vitriol mixing, cooled and filtered get filtrate and obtain mixture M 2;
(3) described mixture M 2 is carried out the first concentrated obtained mixture M 3;
(4) the second concentrated obtained mixture M 4 will be carried out after described mixture M 3 and organic solvent mixing;
(5) described mixture M 4 drying under reduced pressure is obtained Choline Glycerophosphate crystal.
Pass through technique scheme, the invention provides a kind of preparation method of Choline Glycerophosphate crystal, first this preparation method for obtain mixture M 1 by Choline Glycerophosphate and alcohol mixed dissolution, then mixture M 1 and vitriol hybrid filtering are got filtrate and obtain mixture M 2, afterwards concentrated and organic solvent mixes and secondary concentration obtains mixture M 4, finally mixture M 4 drying under reduced pressure is obtained Choline Glycerophosphate crystal, Choline Glycerophosphate crystal habit prepared by this method is different from commercially available Choline Glycerophosphate, water-intake rate is low in atmosphere, thus water content is few, purity is high, there are higher nourishing function and pharmaceutical use.
Other features and advantages of the present invention are described in detail in embodiment part subsequently.
Embodiment
Below the specific embodiment of the present invention is described in detail.Should be understood that, embodiment described herein, only for instruction and explanation of the present invention, is not limited to the present invention.
The invention provides a kind of preparation method of Choline Glycerophosphate crystal, this preparation method comprises:
(1) by Choline Glycerophosphate and the obtained mixture M 1 of alcohol mixing;
(2) by described mixture M 1 and vitriol mixing, cooled and filtered get filtrate and obtain mixture M 2;
(3) described mixture M 2 is carried out the first concentrated obtained mixture M 3;
(4) the second concentrated obtained mixture M 4 will be carried out after described mixture M 3 and organic solvent mixing;
(5) described mixture M 4 drying under reduced pressure is obtained Choline Glycerophosphate crystal.
In the present invention, the consumption of alcohol can be selected in wide scope, and in order to enable Choline Glycerophosphate dissolve quickly, preferably, relative to the Choline Glycerophosphate of 100 weight parts, the consumption of alcohol is 450-550 weight part.
Certainly, the concrete kind of alcohol can be selected in wide scope, can being selected from one or more in methyl alcohol, ethanol, propyl alcohol and ethylene glycol, dissolving more fully to enable Choline Glycerophosphate, preferably, alcohol is selected from one or more in methyl alcohol, ethanol and propyl alcohol.
Similarly, in step (1), the temperature of mixing and mode all can be selected in wide scope, in order to enable Choline Glycerophosphate dissolve quickly, preferably, in step (1), the temperature of mixing is 35-40 DEG C, and is mixed into and is uniformly mixed.
Meanwhile, the time be uniformly mixed does not do special restriction yet, and preferably, the churning time of mixing is 20-40min.
In the present invention, in step (2), the concrete kind of vitriol has diversity, can be sodium sulfate and potassium sulfate, also can be magnesium sulfate and ammonium sulfate, can also be copper sulfate and zinc sulfate, has lower water-intake rate to make the Choline Glycerophosphate crystal obtained, preferably, vitriol is selected from one or more in sodium sulfate, potassium sulfate, magnesium sulfate and copper sulfate.
Certainly, the consumption of vitriol also can be selected in wide scope, and in order to make the aerial water-intake rate of Choline Glycerophosphate crystal that obtains lower, preferably, relative to the mixture M 1 of 100 weight parts, the consumption of vitriol is 30-40 weight part.
Meanwhile, in step (2), the temperature and time of cooling all can be selected in wide scope, and in order to make crystal generate faster, preferably, cooling at least meets the following conditions: cooling temperature is 25-30 DEG C, and cooling time is 30-50min.
In the present invention, in step (3), the first condition concentrated all can be selected in wide scope, in order to make crystal separate out sooner, preferably, the first condition concentrated is: thickening temperature is 30-40 DEG C, concentrated pressure is 40-60KPa, and concentration time is 1h-3h.
Similarly, in step (4), the consumption of organic solvent can be selected in wide scope, in order to make the aerial water-intake rate of Choline Glycerophosphate crystal that obtains lower, preferably, relative to the described mixture M 3 of 100 weight parts, in step (4), the consumption of described organic solvent is 50-70 weight part.
Certainly, the kind of organic solvent has diversity, can be one or more in ethanol, acetone and polyvinylpyrrolidone, and in order to make the aerial water-intake rate of Choline Glycerophosphate crystal that obtains lower, preferably, organic solvent is ethanol and/or acetone.
Certainly, in step (4), the second temperature and time concentrated all can be selected in wide scope, and in order to make crystal separate out faster, preferably, the second temperature concentrated is lower than 40 DEG C, and the second time concentrated was 1h-2h;
In the present invention, the pressure and temperature of empty drying under reduced pressure all can be selected in wide scope, in order to make the aerial water-intake rate of Choline Glycerophosphate crystal that obtains lower, preferably, the condition of drying under reduced pressure is: drying pressure is 0.5-0.8MPa, time of drying is 1-4h, and drying temperature is 35-45 DEG C.
Below will be described the present invention by embodiment.In following examples, water ratio parameter is recorded by weighting method, and Choline Glycerophosphate is purchased from Wuhan Merck medication chemistry company limited.
Embodiment 1
(1) at 38 DEG C, Choline Glycerophosphate and methyl alcohol (weight ratio is 100:500) mix and blend 30min are obtained mixture M 1;
(2) mixture M 1 and sodium sulfate (weight ratio is 100:35) are mixed, at 28 DEG C, cool 40min, then carry out the first filtration and get filtrate obtaining mixture M 2;
(3) under 35 DEG C of conditions with 50KPa, mixture M 2 is carried out the first concentrated 2h and obtain mixture M 3;
(4) by mixed to mixture M 3 and ethanol (weight ratio is 100:60) be incorporated in 35 DEG C at carry out the second concentrated 1.5h and obtain mixture M 4;
(5) at 40 DEG C, mixture M 4 dry 3h under 0.7MPa is obtained Choline Glycerophosphate crystal A1.
Embodiment 2
(1) at 35 DEG C, Choline Glycerophosphate and ethanol (weight ratio is 100:450) mix and blend 40min are obtained mixture M 1;
(2) mixture M 1 and potassium sulfate (weight ratio is 100:35) are mixed, at 25 DEG C, cool 30min, then carry out the first filtration and get filtrate obtaining mixture M 2;
(3) under 30 DEG C of conditions with 40KPa, mixture M 2 is carried out the first concentrated 1h and obtain mixture M 3;
(4) by mixed to mixture M 3 and acetone (weight ratio is 100:50) be incorporated in 30 DEG C at carry out the second concentrated 1h and obtain mixture M 4;
(5) at 35 DEG C, mixture M 4 dry 1h under 0.5MPa is obtained Choline Glycerophosphate crystal A2.
Embodiment 3
(1) at 40 DEG C, Choline Glycerophosphate and propyl alcohol (weight ratio is 100:550) mix and blend 20min are obtained mixture M 1;
(2) mixture M 1 and magnesium sulfate (weight ratio is 100:40) are mixed, at 30 DEG C, cool 50min, then carry out the first filtration and get filtrate obtaining mixture M 2;
(3) under 40 DEG C of conditions with 60KPa, mixture M 2 is carried out the first concentrated 3h and obtain mixture M 3;
(4) by mixed to mixture M 3 and acetone (weight ratio is 100:70) be incorporated in 38 DEG C at carry out the second concentrated 2h and obtain mixture M 4;
(5) at 45 DEG C, mixture M 4 dry 4h under 0.8MPa is obtained Choline Glycerophosphate crystal A3.
Embodiment 4
Choline Glycerophosphate crystal A4 is obtained according to the method for embodiment 1, unlike, in step (2), sodium sulfate is changed to copper sulfate.
Comparative example 1
Choline Glycerophosphate crystal B1 is obtained according to the method for embodiment 1, unlike, do not carry out the process of step (3).
Comparative example 2
Choline Glycerophosphate crystal B2 is obtained according to the method for embodiment 1, unlike, do not carry out the process of step (4).
Test example 1
By Choline Glycerophosphate crystal A1-A3 prepared by commercially available Choline Glycerophosphate S (purchased from Wuhan Merck medication chemistry company limited) and the present invention, B1-B2 weighs and obtains initial weight m1, then being placed on atmospheric moisture is 2h in the air of 30%, weigh weight m2 after obtaining absorbing water, water-intake rate (w/%)=[(m2-m1)/m1] × 100%.
Table 1
| Numbering | Water-intake rate (w/%) |
| A1 | 1.9 |
| A2 | 1.8 |
| A3 | 1.8 |
| A4 | 1.9 |
| B1 | 12.2 |
| B2 | 13.4 |
| S | 16.6 |
As shown in Table 1, after Choline Glycerophosphate crystal provided by the invention places 2h in atmosphere, water-intake rate is very low, relative to A1-A4, the water-intake rate of S obviously increases, describe the aerial water-intake rate of Choline Glycerophosphate crystal prepared by present method less, thus purity is higher, drug effect is stronger; Also increase to some extent relative to the water-intake rate of A1-A4, B1-B2, describe between preparation process provided by the invention (3) and (4) and there occurs synergy, all contribution has been made to the water-intake rate reducing Choline Glycerophosphate crystal.
More than describe the preferred embodiment of the present invention in detail; but the present invention is not limited to the detail in above-mentioned embodiment, within the scope of technical conceive of the present invention; can carry out multiple simple variant to technical scheme of the present invention, these simple variant all belong to protection scope of the present invention.
It should be noted that in addition, each concrete technical characteristic described in above-mentioned embodiment, in reconcilable situation, can be combined by any suitable mode, in order to avoid unnecessary repetition, the present invention illustrates no longer separately to various possible array mode.
In addition, also can carry out arbitrary combination between various different embodiment of the present invention, as long as it is without prejudice to thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (10)
1. a preparation method for Choline Glycerophosphate crystal, is characterized in that, described preparation method comprises:
(1) by Choline Glycerophosphate and the obtained mixture M 1 of alcohol mixing;
(2) by described mixture M 1 and vitriol mixing, cooled and filtered get filtrate and obtain mixture M 2;
(3) described mixture M 2 is carried out the first concentrated obtained mixture M 3;
(4) the second concentrated obtained mixture M 4 will be carried out after described mixture M 3 and organic solvent mixing;
(5) described mixture M 4 drying under reduced pressure is obtained Choline Glycerophosphate crystal.
2. preparation method according to claim 1, wherein, in step (1), relative to the described Choline Glycerophosphate of 100 weight parts, the consumption of described alcohol is 450-550 weight part;
Preferably, described alcohol is selected from one or more in methyl alcohol, ethanol and propyl alcohol.
3. preparation method according to claim 2, wherein, in step (1), the temperature of described mixing is 35-40 DEG C, and described in be mixed into and be uniformly mixed.
4. preparation method according to claim 3, wherein, described in the churning time that is uniformly mixed be 20-40min.
5. according to the preparation method in claim 1-4 described in any one, wherein, in step (2), described vitriol be selected from sodium sulfate, potassium sulfate, magnesium sulfate and copper sulfate one or more.
6. preparation method according to claim 5, wherein, in step (2), relative to the described mixture M 1 of 100 weight parts, the consumption of described vitriol is 30-40 weight part.
7. preparation method according to claim 5, wherein, in step (2), described cooling at least meets the following conditions: cooling temperature is 25-30 DEG C, and cooling time is 30-50min.
8. preparation method according to claim 7, wherein, in step (3), the described first condition concentrated is: thickening temperature is 30-40 DEG C, and concentrated pressure is 40-60KPa, and concentration time is 1h-3h.
9. preparation method according to claim 7, wherein, in step (4), relative to the described mixture M 3 of 100 weight parts, the consumption of described organic solvent is 50-70 weight part;
Preferably, described organic solvent is ethanol and/or acetone.
10. preparation method according to claim 1, wherein, in step (4), the described second temperature concentrated is lower than 40 DEG C, and the second time concentrated was 1h-2h;
Preferably, in step (5), the condition of described drying under reduced pressure is: drying pressure is 0.5-0.8MPa, and time of drying is 1-4h, and drying temperature is 35-45 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510497093.8A CN105001256B (en) | 2015-08-12 | 2015-08-12 | The preparation method of Choline Glycerophosphate crystal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510497093.8A CN105001256B (en) | 2015-08-12 | 2015-08-12 | The preparation method of Choline Glycerophosphate crystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105001256A true CN105001256A (en) | 2015-10-28 |
| CN105001256B CN105001256B (en) | 2018-09-25 |
Family
ID=54374153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510497093.8A Active CN105001256B (en) | 2015-08-12 | 2015-08-12 | The preparation method of Choline Glycerophosphate crystal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105001256B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920609A (en) * | 2016-06-08 | 2016-09-07 | 芜湖福民生物药业有限公司 | Choline alfoscerate-containing medicine and preparation method thereof |
| CN115536710A (en) * | 2022-10-18 | 2022-12-30 | 南京工业大学 | Preparation method of high-quality cytidine sulfate crystal |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523450A (en) * | 1992-01-22 | 1996-06-04 | Genzyme Limited | Crystallization process for preparing glycerophosphocholine |
| CN1560057A (en) * | 2004-03-10 | 2005-01-05 | 山东师范大学 | Preparationj process of high pureness phosphatidyl inositol |
| CN103172659A (en) * | 2013-03-29 | 2013-06-26 | 山东罗欣药业股份有限公司 | L-alpha-glyceryl phosphoryl choline crystal form compound |
| CN103304594A (en) * | 2013-06-18 | 2013-09-18 | 上海科利生物医药有限公司 | Preparation method of L-alpha-glycerophosphoryl choline |
| CN103429603A (en) * | 2011-03-14 | 2013-12-04 | 株式会社韩西克慕 | I- and II-type crystals of L-a-glyceryl phosphoryl choline, and method for preparing same |
-
2015
- 2015-08-12 CN CN201510497093.8A patent/CN105001256B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523450A (en) * | 1992-01-22 | 1996-06-04 | Genzyme Limited | Crystallization process for preparing glycerophosphocholine |
| CN1560057A (en) * | 2004-03-10 | 2005-01-05 | 山东师范大学 | Preparationj process of high pureness phosphatidyl inositol |
| CN103429603A (en) * | 2011-03-14 | 2013-12-04 | 株式会社韩西克慕 | I- and II-type crystals of L-a-glyceryl phosphoryl choline, and method for preparing same |
| US20130345464A1 (en) * | 2011-03-14 | 2013-12-26 | Hanseochem co., ltd | I-and ii-type crystals of l-a-glyceryl phosphoryl choline, and method for preparing same |
| CN103172659A (en) * | 2013-03-29 | 2013-06-26 | 山东罗欣药业股份有限公司 | L-alpha-glyceryl phosphoryl choline crystal form compound |
| CN103304594A (en) * | 2013-06-18 | 2013-09-18 | 上海科利生物医药有限公司 | Preparation method of L-alpha-glycerophosphoryl choline |
Non-Patent Citations (3)
| Title |
|---|
| 赵成磊: "甘油磷酸胆碱晶体的制备及结构分析", 《合肥工业大学学报（自然科学版）》 * |
| 赵成磊: "甘油磷酸胆碱的结晶_结构解析及年产100吨原料药工艺设计", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 * |
| 鹿保鑫: "甘油磷酸胆碱制备及纯化技术研究进展", 《黑龙江》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920609A (en) * | 2016-06-08 | 2016-09-07 | 芜湖福民生物药业有限公司 | Choline alfoscerate-containing medicine and preparation method thereof |
| CN115536710A (en) * | 2022-10-18 | 2022-12-30 | 南京工业大学 | Preparation method of high-quality cytidine sulfate crystal |
| CN115536710B (en) * | 2022-10-18 | 2024-04-16 | 南京工业大学 | Preparation method of high-quality cytidine sulfate crystal |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105001256B (en) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104206561B (en) | A kind of preparation technology of peony seed oil microcapsule powder | |
| CN104622710B (en) | Preparation and application of salicylic acid and chitosan compound composition | |
| SI3110399T1 (en) | Process for producing a stable low concentration, injectable solution of noradrenaline | |
| CN105001256A (en) | Preparation method of choline alfoscerate crystal | |
| CN104922073A (en) | Soluble florfenicol powder and preparation method thereof | |
| CN103251572B (en) | Preparation method of theaflavin enteric microcapsule, as well as product prepared by preparation method and application of product | |
| CN104892909A (en) | Preparation method of polyethyleneglycol monomethyl ether-polylactic acid block copolymer | |
| KR20220082812A (en) | Xanthophyll composition with enhanced bioavailability comprising lutein and zeaxanthin | |
| CN105061494A (en) | Preparation method of choline glycerophosphate crystal | |
| CN105125570A (en) | Medicine composite containing erythromycin thiocyanate and preparation method thereof | |
| CN109673736A (en) | A kind of preparation method of ellagic acid-PVP food fresh keeping solid dispersions | |
| CN105131029B (en) | The preparation method of Choline Glycerophosphate crystal | |
| CN105475700A (en) | Food antioxidant additive containing sucrose monostearate by taking soya lecithin as main raw material | |
| KR101678824B1 (en) | Method for producing Hibiscus cannabinus extract with enhanced antioxidant activity and kaempferitrin content | |
| CN108174925B (en) | Dairy product and method for producing the same | |
| RU2438685C1 (en) | Method of producing shelf fungus extract | |
| KR20140062926A (en) | Slow release carrier of green tea cells and the cosmetic composition containing the same | |
| CN104605003A (en) | Drying method for swim bladder | |
| CN104971043B (en) | A kind of ginkgo Damo liposomal pharmaceutical preparation and preparation method thereof | |
| CN105211977A (en) | Blueberry drink and preparation method thereof | |
| CN107625132A (en) | A kind of feature tea oil microcapsules and preparation method thereof | |
| CN103690980A (en) | Aromatic sterilization purification spraying agent and preparation method thereof | |
| CN105029281A (en) | Method for preparing grape seed extract sterile solution | |
| CN103417488A (en) | Adprin preparation for resisting coccidiosis and preparation method | |
| CN107823463A (en) | A kind of Chinese Drug Gualouzi of medicine-food two-purpose, PERICARPIUM TRICHOSANTHIS preparation and processing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zheng Zhiqiang Inventor before: Su Funan |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 241000 Factory Building 3, Xinghuo Industrial Park, Wuhu High tech Development Zone, Wuhu City, Anhui Province Patentee after: WUHU FOMAN BIOPHARMA CO.,LTD. Country or region after: China Address before: 241000 the 3 factory building of Spark Industrial Park, high tech Development Zone, Wuhu, Anhui. Patentee before: WUHU FOMAN BIOPHARMA Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |